Jefferies Financial Group Inc. Makes New Investment in Beta Bionics, Inc. $BBNX

Jefferies Financial Group Inc. acquired a new stake in Beta Bionics, Inc. (NASDAQ:BBNX – Free Report) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 90,015 shares of the company’s stock, valued at approximately $1,708,000. Jefferies Financial Group Inc. owned approximately 0.17% of Beta Bionics as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Legal & General Group Plc acquired a new stake in shares of Beta Bionics during the 2nd quarter valued at about $62,000. Commonwealth Equity Services LLC raised its position in Beta Bionics by 34.7% in the third quarter. Commonwealth Equity Services LLC now owns 31,795 shares of the company’s stock worth $603,000 after purchasing an additional 8,196 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new position in Beta Bionics in the second quarter worth about $172,000. Ieq Capital LLC bought a new position in Beta Bionics during the second quarter worth about $229,000. Finally, Quantbot Technologies LP bought a new position in Beta Bionics during the second quarter worth about $264,000.

Insiders Place Their Bets

In other Beta Bionics news, Director Christy Jones sold 6,430 shares of the stock in a transaction dated Tuesday, September 22nd. The shares were sold at an average price of $23.00, for a total transaction of $147,890.00. Following the sale, the director owned 19,564 shares of the company’s stock, valued at $449,972. This represents a 24.74% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Steven Russell sold 4,221 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $19.11, for a total transaction of $80,663.31. Following the completion of the sale, the insider owned 169,628 shares of the company’s stock, valued at $3,241,591.08. The trade was a 2.43% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 103,069 shares of company stock valued at $2,014,358 over the last three months. Company insiders own 5.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on BBNX. UBS Group reaffirmed a “buy” rating and set a $25.00 price objective on shares of Beta Bionics in a report on Tuesday, September 15th. Piper Sandler reissued an “overweight” rating and issued a $24.00 target price (up from $20.00) on shares of Beta Bionics in a report on Wednesday, October 28th. Bank of America raised their target price on Beta Bionics from $18.00 to $20.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 15th. Truist Financial boosted their price target on Beta Bionics from $23.00 to $28.00 and gave the company a “buy” rating in a research note on Thursday, September 24th. Finally, Leerink Partners boosted their price target on Beta Bionics from $24.00 to $27.00 and gave the company an “outperform” rating in a research note on Monday, September 14th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $23.69.

Check Out Our Latest Stock Report on Beta Bionics

Beta Bionics Stock Performance

Shares of BBNX opened at $16.42 on Monday. The stock has a fifty day moving average price of $18.47 and a two-hundred day moving average price of $14.86. Beta Bionics, Inc. has a 52-week low of $8.80 and a 52-week high of $32.71. The company has a market cap of $892.71 million, a price-to-earnings ratio of -8.92 and a beta of 3.44.

Beta Bionics (NASDAQ:BBNX – Get Free Report) last announced its earnings results on Tuesday, October 27th. The company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.01. Beta Bionics had a negative return on equity of 27.33% and a negative net margin of 65.31%. The company had revenue of $35.51 million for the quarter. As a group, research analysts predict that Beta Bionics, Inc. will post -2.04 EPS for the current fiscal year.

Beta Bionics Profile

(Free Report)

Beta Bionics, Inc. develops medical technology for people with insulin-dependent diabetes. Its main product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to help manage blood glucose levels with less manual adjustment by users. The iLet system combines an insulin pump with dosing software that works with a continuous glucose monitor. Rather than requiring users to enter detailed insulin settings, it is initialized using the user’s body weight and adjusts insulin delivery based on glucose readings.

See Also

Want to see what other hedge funds are holding BBNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Beta Bionics, Inc. (NASDAQ:BBNX – Free Report).

Institutional Ownership by Quarter for Beta Bionics (NASDAQ:BBNX)

Receive News & Ratings for Beta Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beta Bionics and related companies with MarketBeat.com's FREE daily email newsletter.